IXICO and VirtualScopics Alliance Update

IXICO today announced that together with its alliance partner, VirtualScopics, Inc. (Ticker: VSCP) (‘VirtualScopics’), it has been awarded contracts with two top 15 pharmaceutical companies, one in metastatic solid tumours and one in a rare neurodegenerative disease. IXICO’s TrialTracker™ digital platform will be deployed in both studies to collect and manage imaging data and in the neurodegeneration study, IXICO’s Assessa® digital technology will be used to analyse MRI data collected from patients.

The metastatic solid tumour study will make use of VirtualScopics extensive expertise applying FDG-PET (Fludeoxyglucose PET) to measuring disease progression in oncology and will involve working with imaging centres across North America and Europe. The study is expected to complete in June 2017.

By |2017-10-11T12:27:56+00:0029 June 2015|Collaboration|